
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has demonstrated strong financial performance in 3Q25, achieving revenue growth across all three segments: Vision Care saw an 8% year-over-year increase with $736 million in revenue, Surgical grew 4% to $215 million, and Pharmaceuticals also rose by 8% to $330 million. Notably, the company is experiencing significant product-specific growth, exemplified by MIEBO's impressive 110% year-over-year prescription growth, which positions it to potentially surpass XIIDRA in the dry eye market by the end of 2025. Furthermore, management has provided positive guidance for 2025, indicating that the company is regaining momentum after its spin-off and continuing to improve its financial outlook despite a net loss of $28 million in the latest quarter.
Bears say
Bausch & Lomb faces significant challenges in maintaining its competitive position in the ophthalmology market, hampered by intense competition and promotional sensitivity among customers. The company's growth prospects appear limited due to a constrained product pipeline and high leverage following its acquisition of Xiidra, which could hinder future mergers and acquisitions necessary for expansion. Additionally, macroeconomic pressures and uncertainty surrounding elective procedures, along with risks tied to potential litigation with its former parent company, contribute to a negative outlook for the firm’s stock performance.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares